Literature DB >> 21748500

Routine management of volume status after aneurysmal subarachnoid hemorrhage.

Stefan Wolf1.   

Abstract

Prophylactic use of hypervolemia and hypertension is believed to present an option to decrease the incidence of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage and improve neurologic outcome. A Medline literature search was conducted to review available evidence regarding volume management after subarachnoid hemorrhage. Quality of selected studies was evaluated, using the standardized GRADE system. Eleven studies focused on prophylactic hypervolemic therapy after aneurysmal subarachnoid hemorrhage were identified, including four randomized controlled trials. Available studies showed a large heterogeneity in physiologic treatment goals and interventions applied. The oldest and smallest randomized controlled trial suggested a positive effect, but had severe limitations in trial design. Neither of the other randomized controlled studies showed outcome benefit with hypervolemic therapy. Results from observational studies were not found to support the use of prophylactic hypervolemia and hypertension. Complication frequency was repeatedly reported to be higher with the application of prophylactic hypervolemia. In summary, prophylactic hyperdynamic therapy after subarachnoid hemorrhage has not been adequately shown to effectively raise cerebral blood flow or improve neurological outcome. In contrast, there is evidence for harm using overly aggressive hydration.

Entities:  

Mesh:

Year:  2011        PMID: 21748500     DOI: 10.1007/s12028-011-9593-9

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  19 in total

1.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

2.  Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage.

Authors:  Rachel Meyer; Steven Deem; N David Yanez; Michael Souter; Arthur Lam; Miriam M Treggiari
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

Review 3.  Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review.

Authors:  Jan W Dankbaar; Arjen Jc Slooter; Gabriel Je Rinkel; Irene C van der Schaaf
Journal:  Crit Care       Date:  2010-02-22       Impact factor: 9.097

4.  Effects of intravascular volume expansion on cerebral blood flow in patients with ruptured cerebral aneurysms.

Authors:  I Yamakami; K Isobe; A Yamaura
Journal:  Neurosurgery       Date:  1987-09       Impact factor: 4.654

Review 5.  Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares.

Authors:  Paul E Marik; Michael Baram; Bobbak Vahid
Journal:  Chest       Date:  2008-07       Impact factor: 9.410

Review 6.  Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.

Authors:  Miriam M Treggiari; Bernhard Walder; Peter M Suter; Jacques-André Romand
Journal:  J Neurosurg       Date:  2003-05       Impact factor: 5.115

7.  Preventive therapy against delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: trials of thromboxane A2 synthetase inhibitor and hyperdynamic therapy.

Authors:  K Yano; T Kuroda; Y Tanabe; H Yamada
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

8.  Control of hypertension and prophylaxis against vasospasm in cases of subarachnoid hemorrhage: a preliminary report.

Authors:  R H Rosenwasser; T E Delgado; W A Buchheit; M H Freed
Journal:  Neurosurgery       Date:  1983-06       Impact factor: 4.654

9.  Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage.

Authors:  Kurt T Kreiter; Stephan A Mayer; George Howard; Volker Knappertz; Don Ilodigwe; Michael A Sloan; R Loch Macdonald
Journal:  Stroke       Date:  2009-05-21       Impact factor: 7.914

10.  Global end-diastolic volume acquired by transpulmonary thermodilution depends on age and gender in awake and spontaneously breathing patients.

Authors:  Stefan Wolf; Alexander Riess; Julia F Landscheidt; Christianto B Lumenta; Patrick Friederich; Ludwig Schürer
Journal:  Crit Care       Date:  2009-12-14       Impact factor: 9.097

View more
  5 in total

1.  Accuracy of Daily Lung Ultrasound for the Detection of Pulmonary Edema Following Subarachnoid Hemorrhage.

Authors:  Craig A Williamson; Ivan Co; Aditya S Pandey; B Gregory Thompson; Venkatakrishna Rajajee
Journal:  Neurocrit Care       Date:  2016-04       Impact factor: 3.210

2.  Association of early post-procedure hemodynamic management with the outcomes of subarachnoid hemorrhage patients.

Authors:  Kazuaki Kuwabara; Kiyohide Fushimi; Shinya Matsuda; Koichi B Ishikawa; Hiromasa Horiguchi; Kenji Fujimori
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

Review 3.  Management of delayed cerebral ischemia after subarachnoid hemorrhage.

Authors:  Charles L Francoeur; Stephan A Mayer
Journal:  Crit Care       Date:  2016-10-14       Impact factor: 9.097

Review 4.  Current controversies in the prediction, diagnosis, and management of cerebral vasospasm: where do we stand?

Authors:  Young Lee; Scott L Zuckerman; J Mocco
Journal:  Neurol Res Int       Date:  2013-10-08

5.  Impact of clipping versus coiling on postoperative hemodynamics and pulmonary edema after subarachnoid hemorrhage.

Authors:  Nobutaka Horie; Mitsutoshi Iwaasa; Eiji Isotani; Shunsuke Ishizaka; Tooru Inoue; Izumi Nagata
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.